Eli Lilly's Orforglipron may become the first drug fast-tracked under the FDA's new program, promising quicker access for ...

The rollout of antiretroviral therapy for HIV showed how global solidarity and smart policy can overcome barriers to new treatments, say Jirair Ratevosian and Jeffrey L Sturchio The arrival of ...

USA: Researchers have reported a potential risk of severe hypercalcemia when tirzepatide, a dual GIP and GLP-1 receptor ...

ENDO 2025 featured the latest research on novel therapies for adrenal and neuroendocrine conditions, new data on various ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat ...

Findings from an international database seem encouraging but could be due to confounders or older GLP-1 receptor agonists.

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live ...

In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, outperforming the group given ...

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated ...

GLP-1 receptor agonists may reduce the likelihood of mortality and increase odds for transplant wait-listing for patients ...

Semaglutide is linked to significant weight loss and glucose levels in adults with schizophrenia, overweight/obesity, and ...

"For them to work effectively, they need to be taken long term," cautioned epidemiologisy professor Reimar W. Thomsen.